Product news

Share this article:

Astellas Pharma won FDA approval for their sNDA for the use of Mycamine (micafungin sodium) for injection in the treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses. Mycamine was approved in 2005 for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplantation.

Alpharma announced the availability of the Flector patch (diclofenac epolamine topical patch) 1.3% in the US. The adhesive patch delivers medication directly to the site of pain, offering a safe and effective alternative to widely used nonsteroidal anti-inflammatory drugs that are taken orally. The targeted delivery of Flector patch through the skin results in minimal systemic absorption of diclofenac.

MiddleBrook Pharmaceuticals received FDA approval of its NDA for once-daily Moxatag tablets 775 mg (amoxicillin extended-release tablets) for the treatment of adults and pediatric patients 12 years and older with pharyngitis and/or tonsillitis secondary to Streptococcus pyogenes (commonly referred to as strep throat).

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies